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Current cell-based repair strategies have proven unsuccessful for treating cartilage
defects and osteoarthritic lesions, consequently advances in innovative therapeutics are
required and mesenchymal stem cell-based (MSC) therapies are an expanding area of
investigation. MSCs are capable of differentiating into multiple cell lineages and exerting
paracrine effects. Due to their easy isolation, expansion, and low immunogenicity,
MSCs are an attractive option for regenerative medicine for joint repair. Recent
studies have identified several MSC tissue reservoirs including in adipose tissue, bone
marrow, cartilage, periosteum, and muscle. MSCs isolated from these discrete tissue
niches exhibit distinct biological activities, and have enhanced regenerative potentials
for different tissue types. Each MSC type has advantages and disadvantages for
cartilage repair and their use in a clinical setting is a balance between expediency
and effectiveness. In this review we explore the challenges associated with cartilage
repair and regeneration using MSC-based cell therapies and provide an overview of
phenotype, biological activities, and functional properties for each MSC population. This
paper also specifically explores the therapeutic potential of each type of MSC, particularly
focusing on which cells are capable of producing stratified hyaline-like articular cartilage
regeneration. Finally we highlight areas for future investigation. Given that patients present
with a variety of problems it is unlikely that cartilage regeneration will be a simple “one
size fits all,” but more likely an array of solutions that need to be applied systematically
to achieve regeneration of a biomechanically competent repair tissue.
Keywords: Mesenchymal stem cell (MSC), articular cartilage, adipose tissue, bone marrow, synovial joint, tissue
engineering
INTRODUCTION
Osteoarthritis (OA) is the progressive loss of normal joint function and is characterized by the
degeneration of articular cartilage leading to pain, stiffness, and loss of joint mobility. OA is
the world’s leading cause of physical disability in adults, in the UK 20% of adults aged between
50–59 and 50% aged between 80–89 have symptomatic disease in one or both knee joints (Lacey
et al., 2008). Current treatments for OA generally involve managing pain and inflammation,
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physiotherapy and lifestyle modifications in order to slow the
progression of disease. When conservative forms of therapy are
exhausted, patients and their rheumatologists may elect to have
surgery.
Joint cartilage degeneration has multiple causes;
biomechanical stress, metabolic and genetic defects, and, in
many cases first manifests as a focal chondral or osteochondral
lesion. Lesions can spread over the rest of the joint surface as
the edges of the defect are more susceptible to degenerative
change due to inequalities in biomechanical stress (Lefkoe
et al., 1993; Braman et al., 2005). Much research has focused
on repairing focal surface defects in order to spare the joint
from further degeneration and recover pain free movement.
A fundamental barrier to restoration of cartilage integrity is
its slow intrinsic repair capacity that is largely attributable to
a lack of vascularity, relatively low cellularity in adult tissue,
and the presence of a dense hydrated extracellular matrix
that inhibits cellular migration to and from the site of injury.
Repair of lesions above a critical size of 3–5mm in diameter
must be initiated through extrinsic mechanisms such as
microfracture of the subchondral bone plate to release blood
and marrow into the defect to form a clot and fibrocartilaginous
repair tissue (Pridie, 1959). A related technique, autologous
chondrocyte implantation (ACI), is a two-part procedure,
first the isolation and expansion of chondrocytes from intact
non-weight-bearing regions of the joint and secondly their
transplantation into an osteochondral defect in a weight-
bearing region (Grande et al., 1989; Brittberg et al., 1994). The
limited expansion capacity of dedifferentiated chondrocytes
and their increasing inefficiency at redifferentiation during
extended culture has led to the use of mesenchymal stem
cells (MSCs) for autologous cartilage repair of larger defects
(Wakitani et al., 1994). MSCs are found in numerous human
tissues including bone marrow and adipose tissue. These
MSCs have been shown to differentiate into bone, cartilage,
muscle, and adipose tissue. Further studies have also shown
cells displaying the properties of adult-derived MSCs can
be isolated from the synovial joint tissues such as articular
cartilage and synovial membrane (Alsalameh et al., 2004;
Dowthwaite et al., 2004; Williams et al., 2010; McCarthy et al.,
2012).
Cell-based therapy is becoming an established element of
modern healthcare and is predicted to grow as knowledge and
implementation of cell biology, biomaterials, and regenerative
medicine increases. The aim of this article is to provide an
overview of mesenchymal stem cell-based therapies for the
treatment of lesion in articular cartilage. In the absence of
disease modifying pharmacological agents (Mobasheri, 2013a)
or biological therapies (Mobasheri, 2013b), cell-based therapies
are one of the few available treatments for focal cartilage and
osteoarthritic defects. In this review article we describe the
significance of this topic in the context of the biology of the
joint and the osteoarthritic disease process, and summarize
key concepts and developments in the area of MSC-based
therapies.
ARTICULAR CARTILAGE AND THE
CHONDROCYTE
Articular cartilage is a smooth, thin and opalescent layer of
hyaline tissue that covers the surface of bones of synovial joints
(Figure 1). It is a highly organized and specialized tissue that
permits free articulation, painless movement, and transmission
of force through the skeleton due to the avascular, alymphatic
and aneural composition. Compared to other tissues, articular
cartilage has a low rate of metabolic activity (Pearle et al.,
2005). The tissue is maintained by a single sparsely distributed
cell, the chondrocyte (Archer and Francis-West, 2003a), that is
surrounded by a highly hydrated extracellular matrix (ECM). The
structure of cartilage is primarily composed of a highly organized
collagen network that supports aggregating proteoglycans (PGs)
and hyaluronan (HA) that is the most abundant non-PG forming
glycosaminoglycan (GAG) in the cartilage matrix (Jeffery et al.,
1991). Articular cartilage is divided into four zones; the
superficial (tangential), transitional, radial, and calcified zones
(Eyre, 2002). The physical and biochemical differences between
the zones is important to allow cartilage to resist both extrinsic
and intrinsic forces (Knudson and Knudson, 2001). In addition
to the pseudo-stratified appearance of the matrix, it can be
further subdivided by its composition around chondrocytes
as pericellular, territorial and inter-territorial matrices. The
collagen fibril arrangement and orientation, cellular density
and proteoglycan composition vary with depth to provide the
diverse mechanical properties required across the joint. The
main collagens (type II, IX, and XI) provide tensile strength
and the main proteoglycan, aggrecan, delivers compressive
stiffness. Small proteoglycans, including decorin, biglycan, and
fibromodulin, bind to other matrix macromolecules and thereby
help to stabilize the matrix (Buckwalter and Mankin, 1998).
Chondrocyte-matrix interactions are mediated through the
pericellular and territorial matrices, facilitated by collagen type
VI and non-collagenous proteins such as anchorin CII, tenascin,
and fibronectin (Poole et al., 2001). This allows mechanical,
electrical, and physicochemical signal transduction to the
chondrocytes, directing the synthetic and degradative activity
of chondrocytes (Mobasheri et al., 2002; Millward-Sadler and
Salter, 2004). Cartilage tissue contains a large proportion of water
(65–80% by wet weight). Chondrocytes themselves constitute 5–
10% of the tissue’s total volume, collagens form 10–30%, whilst
proteoglycans and othermolecules consist of 5–10% of the tissue’s
wet weight (Eyre, 2002; Archer et al., 2003b; Hunziker et al.,
2007).
In adult cartilage, the prime function of articular chondrocytes
is to synthesize and maintain the ECM required for tissue
function. As the tissue is not vascularized it relies on diffusion
from the articular surface for nutrient and metabolite exchange;
therefore, chondrocytes are adapted to operate at a low oxygen
tensions (ranging from 5% at the surface to<1% in the mid/deep
layers) with the majority of the cell’s energy requirements
coming from glycolysis (Lafont, 2010). Despite mature articular
chondrocytes having a relatively lowmetabolic rate, they display a
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FIGURE 1 | Schematic representation of the organization of articular cartilage. (A) Articular cartilage is a thin layer of hyaline tissue that covers the surface of
bones in synovial joints. (B) The tissue is divided into four zones; the superficial (tangential), transitional, radial, and calcified zones. (C) The hyaline cartilage matrix can
be subdivided by its composition around chondrocytes as pericellular, territorial and inter-territorial matrices. The collagens (primarily collagen type II, IX, and XI)
provide tensile strength and the main proteoglycan, aggrecan, is responsible for compressive stiffness. Chondrocyte-matrix interactions are mediated through plasma
membrane receptors such as integrins and CD44.
remarkable synthetic capacity. The cartilage ECM is continually
remodeled as chondrocytes replace matrix macromolecules lost
through degradation as part of normal turnover (Goldring
and Marcu, 2009). ECM maintenance depends on the ability
of chondrocytes to detect alterations in the macromolecular
composition and organization of the matrix, such as the presence
of degraded macromolecules, and to respond by synthesizing
appropriate types and amounts of new ECM components.
The balance between catabolism and anabolism of the ECM
maintains the healthy cartilage structure; a loss of equilibrium
can lead to degeneration (Goldring andMarcu, 2009; Bader et al.,
2011). During aging and disease, tissue homeostasis is disrupted;
the rate of loss of ECM exceeds the rate of deposition of newly
synthesized molecules (Goldring and Marcu, 2009). Although
articular cartilage can tolerate repetitive physical loading, it has
a low capacity for self-repair, therefore, an inability to quickly
heal minor injuries makes cartilage particularly sensitive to
progressive damage and degenerative diseases such as OA.
CARTILAGE DAMAGE AND OA
Articular cartilage defects caused by trauma or chronic injury
are classified into two categories: Partial-thickness and full-
thickness (Hunziker, 1999). Partial-thickness or chondral defects
do not penetrate to the subchondral bone and therefore rely
on healing through intrinsic processes that are limited by the
tissue’s inherent characteristics. There is evidence of transient
chondrocyte proliferation at wound sites, however, there is little
or no cellular migration into the injured sites to repair the
defect (Hunziker and Rosenberg, 1996; Zhang et al., 2009).
Furthermore, the reparative response usually terminates before
the cartilage defect is fully healed, resulting in a lasting defect
of mainly acellular tissue that reduces tissue function leading to
further tissue degeneration (Hunziker, 1999; Zhang et al., 2009).
Full-thickness osteochondral defects penetrate the entire
thickness of articular cartilage to the subchondral bone. Unlike
partial-thickness defects, full-thickness defects are accessible to
MSCs, macrophages, and blood cells, if there is a break in the
underlying subchondral bone plate. In the latter case, a fibrin clot
fills the defect and MSCs from bone marrow migrate into the
repair matrix. Gradually MSCs replace the fibrin clot, stem cells
differentiate into chondrocytes and secrete a proteoglycan-rich
ECM to remodel the damaged area (Hunziker, 1999). However, it
is frequently reported that a fibrous repair tissue is formed, which
has weaker biomechanical properties and higher permeability
(Kreuz et al., 2006). Consequently, the spontaneous repair
process in full-thickness defects is a transient phenomenon and
tissue degeneration eventually re-occurs. At this point, complete
resurfacing is rarely observed leading to the development of
secondary OA.
OA is a disease that affects the whole joint, including
cartilage, subchondral bone, synovium, tendons, and muscles
(Sellam and Berenbaum, 2010; Goldring, 2012; Loeser et al.,
2012; Berenbaum et al., 2013; Mobasheri et al., 2014). The
disease is characterized by degeneration of articular cartilage,
low-grade synovial inflammation, and alterations in the joint
soft tissues and subchondral bone (Goldring and Goldring,
2007; Sellam and Berenbaum, 2010; Mobasheri et al., 2014).
Most commonly, OA occurs as primary or idiopathic OA;
risk factors include obesity, overuse, joint instability, genetic or
anatomical irregularities, metabolic disorders, muscle weakness,
and various disorders of bone turnover (Mobasheri et al., 2014).
The disease progresses in three stages; firstly there are changes
in or loss of the ECM, then chondrocytes attempt to remodel
and repair the tissue and finally, the degeneration occurs to a
greater extent than synthesis causing incremental loss of cartilage
(Hendren and Beeson, 2009). Cartilage degeneration results in
bone-to-bone articulation, inflammation, significant pain, and
disability. A major component of OA is inflammation, there
is an increased activity of many cytokines, chemokines, and
adipokines (Loeser et al., 2012). The inflamed synovium produces
catabolic and pro-inflammatory mediators such as cytokines,
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nitric oxide, prostaglandin E2 (PGE2), and neuropeptides.
These molecules unbalance the matrix degradation and repair
equilibrium resulting in excessive secretion of the proteolytic
enzymes and cartilage ECM breakdown (Goldring and Goldring,
2007; Sellam and Berenbaum, 2010). Cartilage alterations induce
further synovial inflammation, creating a progressive loop that
exacerbates clinical symptoms and stimulates further joint
degradation.
As cartilage ages, there are a number of biochemical and
morphological changes that occur within the tissue that alter the
mechanical properties and decrease the ability of chondrocytes
to maintain articular cartilage (Martin and Buckwalter, 2002).
Damage-induced cellular alterations result in a senescence-
associated secretory phenotype characterized by the production
and secretion of cytokines, chemokines, and proteases (Loeser,
2013; Mobasheri et al., 2014). Oxidative stress and alterations
in mechanical loading can further promote changes in the
chondrocytes. OA is an active, progressive, degenerative disease
that is the common pathway of age related damage, acute injury
and inflammatory degradation of synovial joints.
CARTILAGE REGENERATION AND REPAIR
As mentioned previously cartilage has a poor intrinsic repair
capacity, tears and defects larger than 3mm rarely heal and
potentially can lead to OA of the joint. Poor repair is partly due
to the lack of blood vessels, which are required for efficient repair
responses, and, because of a low cell density with chondrocytes
embedded within lacunae, unable to easily migrate to damaged
areas (Henrotin et al., 2005). Therefore, extrinsic intervention
is often necessary to repair damaged tissue and to prevent
further damage. The most effective treatment for end-stage OA is
arthroplastic prosthetic replacement. However, due to the finite
lifespan of prostheses, this is unsuitable for patients younger
than 45 years. A variety of treatment methods have been used
to repair defects and stimulate the formation of new articular
cartilage. These include lavage, microfracture, osteochondral
allograft transfer system (OATS), ACI and osteotomy (Bhosale
and Richardson, 2008). Each procedure has varied success and
many factors have to be considered including defect size and
patient age when selecting the correct treatment.
The most widely used method that surgeons adopt for
cartilage repair involves penetration of the subchondral bone
causing the release of multipotent MSCs in a process defined
as marrow stimulation. Previous iterations of this method have
included Pridie drilling, spongialization and abrasion therapy,
though the most popular modernmethod is microfracture (Ronn
et al., 2011). Under arthroscopy, tiny fractures are made using
an awl in the subchondral bone, inducing bleeding and a fibrin
clot that is infiltrated with stem cells from the bone marrow.
Stem cells fill the defect, differentiate and form a repair tissue
(Yen et al., 2008) that is fibrocartilaginous and not suitable to
withstand the demands of everyday activities, and thus, at higher
risk of future breakdown (Redman et al., 2005). Microfracture,
however, does offer symptomatic relief; in a follow up study it
was reported that pain was decreased and function improved in
95% of the study population after up to 17 years post-surgery
(Steadman et al., 2003).
An alternative intervention developed by Brittberg and
colleagues, ACI, is currently regarded as the “gold standard” for
cartilage repair (Brittberg et al., 1994). Cartilage is harvested
from a low weight-bearing region, chondrocytes are isolated
and expanded in vitro before being injected into a full-thickness
articular defect under a periosteal patch stitched over the defect
and sealed in with fibrin glue (Brittberg et al., 1994, 2003;
Redman et al., 2005). Implanted chondrocytes begin the process
of producing neo-cartilage through the production of ECM. ACI
has been shown to produce effective and durable repair tissue,
relieving symptoms and clinical success remains high, even after
20 years post-implantation (Peterson et al., 2010). The repair
tissue produced by ACI has been shown to be varied but in
general is more hyaline-like than produced using microfracture.
However, there is often an abundance of type I collagen which
is also characteristic of fibrocartilage (Roberts et al., 2002).
Improvements in the procedure have led to second generation
ACI techniques; synthetic collagen membranes have replaced the
periosteal flap, and several biomaterial and natural scaffolds have
been developed into which the chondrocytes are seeded (Redman
et al., 2005). Despite the encouraging clinical outcomes ACI has
a number of disadvantages; it requires multiple surgeries and is
more invasive than microfracture, treatable defect size is limited
by the finite amount of harvestable donor tissue and the restricted
in vitro expansion of chondrocytes before de-differentiation
makes their use redundant (Barbero et al., 2003). In follow-up
studies, it has been shown that 1 year post-operatively, ACI offers
significantly improved repair compared to microfracture (Visña
et al., 2004); however, after 2–5 years randomized trials show
no significant difference in repair efficiency between ACI and
microfracture (Knutsen et al., 2007; Van Assche et al., 2010). The
limitations of current surgical strategies have led to investigations
into the use of adult stem cells from various tissue sources in
an endeavor to improve hyaline-like cartilaginous repair and
increase the treatable defect size.
MSC PHYSIOLOGY, AND FUNCTION
Friedenstein first characterized clonogenic fibroblast-like cells
extracted from bone marrow via attachment to tissue culture
plastic (Friedenstein et al., 1976). These marrow-derived stromal
cells were found to be inherently osteogenic but displayed
plasticity being capable of differentiating into multiple cell types
of the mesodermal lineage. MSCs have been shown to form
cartilage, bone, adipose tissue, intervertebral disc, ligaments, and
muscle (Prockop, 1997; Pittenger et al., 1999). Therefore, MSCs
are typically defined as adherent, self-renewing, fibroblastoid-
like cells that can differentiate to osteoblasts, adipocytes, and
chondrocytes in vitro (Barry and Murphy, 2004; Phinney and
Prockop, 2007). Self-renewal refers to the biological pathways
and mechanisms that preserve the undifferentiated stem cell
state. In MSCs this capacity for self-renewal is in part due to
telomerase reverse transcriptase (TERT) activity (Kolf et al.,
2007). Additionally, leukemia inhibitory factor (LIF), fibroblast
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growth factors (FGFs), Wnts and other growth factors and
cytokines, have been implicated in maintenance of the MSC
phenotype (Tsutsumi et al., 2001; Metcalf, 2003; Kléber and
Sommer, 2004; Kolf et al., 2007). These factors have also
been shown to be critical for self-renewal and maintenance of
undifferentiated embryonic mesenchymal tissue.
It is widely accepted that primary MSC cultures are a
heterogeneous population of cells with varying capacities of
self-renewal and differentiation (Ho et al., 2008; Phinney,
2012). Their heterogeneity means no singular unique marker is
available for identification and isolation (Table 1). Therefore, a
panel of positive and negative markers must be used for the
selection criteria. MSC populations commonly express surface
proteins including CD29, CD44, CD49a–f, CD51, CD73, CD90,
CD105, CD106, CD166, and Stro1 and must be negative for
hematopoietic lineage markers including CD11b, CD14, and
CD45 (Halfon et al., 2011). The optimal panel of marker for
selection is frequently debated and numerous additional markers
have been reported in the literature. The International Society
of Cellular Therapy recommended that MSCs must meet a
minimum criteria including: Adhesion to plastic, expression of
surface markers CD73, CD90, CD105 (≥95% expression), the
absence of hematopoietic markers CD34, CD45, CD14 or CD11b,
CD79α or CD19 (≤2%), the absence of HLA Class II molecules
and tripotent differentiation into chondrogenic, osteogenic, and
adipogenic phenotypes (Horwitz et al., 2005; Dominici et al.,
2006).
Whilst MSC capacity for multipotent differentiation
represents a great potential for regenerative medicine, beneficial
effects are also achieved by MSC-mediated improvements in
native cell viability and proliferation, reduction in apoptosis and
anti-inflammatory immunomodulatory effects (Caplan, 2009;
Glenn and Whartenby, 2014). These additional reparative effects
are achieved through MSC secretion of paracrine growth factors
and cytokines, direct cell-cell interactions through tunneling
nanotubes and release of extracellular vesicles containing
peptides, mRNA and microRNAs (Figure 2); for a detailed
review of the various MSC repair mechanisms please see Spees
et al. (2016). Treatment of articular cartilage with intra-articular
injection of MSCs has shown that some regeneration of joint
tissues can occur; however, studies have shown that the source
of repair tissue is primarily derived from native cells (Murphy
et al., 2003). In support of the latter studies, Horie and colleagues
showed that inter-articular injection of human MSCs into
the rat knee increased the expression of type II collagen in
resident cells (Horie et al., 2012). These findings indicate that
MSCs also coordinate and enhance the reparative response
rather than exclusively replacing lost and injured tissue (Wyles
et al., 2015). MSC-enhanced repair is induced via secretion of
various anabolic paracrine factors, such as transforming growth
factor beta (TGF-β), vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF) and other bioactive molecules that
modulate reparative responses (Tille and Pepper, 2002; Sorrell
et al., 2009; Freitag et al., 2016). Chondrocytes from end stage
diseased cartilage remain metabolically active and continue to
express genes for cartilaginous matrix molecules, corroborating
the hypothesis that MSCs support repair and modulate these
chondrocytes (Freitag et al., 2016).
Recent studies have revealed that MSCs interact with immune
cells and eliminate survival factors, suppress inflammatory T
cell proliferation, inhibit maturation of monocytes and myeloid
dendritic cells, and re-calibrate the chemokine gradient (Glenn
and Whartenby, 2014). MSCs inhibit several aspects of B cell
activity, including activation, proliferation, chemokine receptor
expression, and differentiation into antibody-secreting plasma
cells (Glenn and Whartenby, 2014). MSCs have also been
shown to induce nitric oxide (NO) in response to inflammatory
cytokines to suppress CD8+ T cell proliferation, cytokine
production, and cytotoxicity (Glenn and Whartenby, 2014).
MSCs also produce many soluble factors including TGF-β,
hepatocyte growth factor (HGF), PGE2 and interleukin 10
(IL-10) that suppress CD4+ T cell proliferation and polarize
them toward T-helper cells (TH1/TH2) and anti-inflammatory
T-regulatory cells (Tregs) (Glenn and Whartenby, 2014),
TABLE 1 | Cell Surface markers for undifferentiated MSCs.
Tissue reservoir Positive markers Negative markers References
Bone marrow CD13, CD29, CD44, CD49a–f, CD51, CD73, CD90,
CD105, CD106, CD166, and STRO-1
CD11b, CD14, CD19 CD34, CD45, and
CD79α
Halfon et al., 2011; Barry and Murphy,
2013
Adipose CD44, CD90, and CD105 CD45, CD34, and CD133 Dominici et al., 2006
Cartilage CD9, CD49e, CD90, CD166, Notch1, and STRO-1 CD45, CD133/−1, and −2 Alsalameh et al., 2004; Fickert et al.,
2004; Williams et al., 2010
Synovial membrane CD44, CD90, CD105, and CD147 CD34, CD45, CD117, and CD31 De Bari et al., 2001b; Sakaguchi et al.,
2005
Synovial fluid CD10, CD13, CD40, CD44, CD55, CD73, CD90,
CD 105, CD 166, and D7-FIB
CD11b, CD34, CD45, and CD271 Jones et al., 2004; Krawetz et al., 2012
Fat pad CD13, CD29, CD44, CD90, and CD105 CD34, CD56, CD271, and STRO1 Khan et al., 2012
Periosteal membrane CD9, CD73, CD90, CD105, SH2, SH3, and SH4 CD11b, CD14, CD19, CD34, CD45,
CD79a, and HLA-DR
Lim et al., 2005; Chang and Knothe
Tate, 2012
Trabecular bone CD44, CD64, CD90, CD105, CD147, and CD166 CD31, CD34, CD45, and CD117 Sakaguchi et al., 2004
Muscle CD34, CD144, and CD56 Zheng et al., 2007
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FIGURE 2 | Mechanisms of MSC mediated repair. (A) Differentiation into replacement cell types. (B) Secretion of paracrine factors such as growth factors,
cytokines, and hormones. Vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), angiopoietin-1 (ANG1), interleukin-10 (IL-10),
prostaglandin E2 (PGE2), nitrous oxide (NO), fibroblast growth factor (FGF-2), Transforming growth factor-beta (TGF-β), insulin-like growth factor-1 (IGF-1). (C) Transfer
of organelles (e.g., mitochondria) and/or molecules through tunneling nanotubes. (D) Transfer of proteins/peptides, RNA, hormones, and/or chemicals by extracellular
vesicles such as exosomes or microvesicles. Exosomes are generated through the endocytic pathway and released through exocytosis. Microvesicles are produced
by cell surface budding and released directly from the plasma membrane. Adapted from Spees et al. (2016).
promoting T cell apoptosis and reduce inflammation, and
providing a favorable environment for tissue repair. After in
vivo administration, MSCs can induce peripheral tolerance and
migrate to injured tissues where they have the capacity to
exert immunosuppressive properties (Glenn and Whartenby,
2014) and inhibit the release of pro-inflammatory cytokines and
promote the survival of existing cells and the repair of damaged
tissue (Uccelli et al., 2008). Using a murine in vivo model of OA
it has been shown that MSCs deactivate macrophages stimulated
by cartilage breakdown products, preventing further catabolism
of the cartilage and also elevating macrophage production of
anabolic growth factors (ter Huurne et al., 2012). Due to
their strong immunomodulatory phenotype MSCs are being
explored clinically for treatment of a variety of immune-mediated
diseases such as motor neuron disease and Sjögren’s syndrome
(Parekkadan and Milwid, 2010).
The versatility of MSCs has led to the development of cellular
therapies for tissue engineering and regenerative medicine.
According to data reported by the US National Institutes of
Health (http://www.clinicaltrial.gov/) there are approximately
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500 clinical trials currently utilizing MSCs as therapy for a
diverse range of disease (Squillaro et al., 2016). MSCs seem
to provide clear benefits over chondrocytes when treating
degenerative conditions such as OA. MSCs can be expanded for
a prolonged period ex vivo due to their capability of self-renewal
and also maintain their phenotype to a greater degree than
dedifferentiated chondrocytes in culture. Additionally, MSCs
have the potential to form all joint tissues and this hypothetically
enables them to repair both lesions in the articular cartilage or
osteochondral defects as well as other joint structures such as
ligaments.
TISSUE RESERVOIRS OF MSCS
The “niche” incorporates all the factors required to regulate stem
cell self-renewal and differentiation including differentiated or
stromal cells in direct or indirect contact with stem cells, ECM
molecules and soluble mediators within the milieu (Schofield,
1978; Kolf et al., 2007). It is believed that certain signals enter
the niche or that stem cell leave the niche in order to initiate
differentiation for regeneration or repopulation of a tissue (Kolf
et al., 2007). Multiple MSC niches have been described within
various tissues (Figure 3) and stem cells housed in them isolated
and utilized for chondrogenic repair. MSCs have been found in
the bone marrow, adipose tissue, articular cartilage, synovium,
skeletal muscle, dental pulp, circulatory system, heart, brain,
umbilical cord tissues (including Wharton’s jelly), and other
connective tissues (Gronthos et al., 2000; Zuk et al., 2001;
Alsalameh et al., 2004; Dowthwaite et al., 2004; Crisan et al., 2008;
Gronthos and Zannettino, 2011; Batsali et al., 2013; Mobasheri
et al., 2014; Steward and Kelly, 2015).
Bone Marrow
Bone marrow is currently the most common MSC source in
the clinical practice and have been extensively used for cartilage
repair either alone or with biological scaffolds. However, there are
some limitations with bone marrow-derived MSCs (BM-MSCs),
in that they are a rare population occurring with a frequency of
0.01–0.001% (Bonab et al., 2006). In addition, the differentiation
potential of BM-MSCs decreases with increased expansion in
vitro (Banfi et al., 2000; Li et al., 2011) and harvesting these cells
involves a painful procedure and causes donor site morbidity.
A clinical study of BM-MSC transplantation for cartilage
repair using passaged bone marrow MSCs suspended in a
collagen type I gel and transplanted with an autologous periosteal
flap showed that 42 weeks post-surgery hyaline cartilage-like
tissue was partially present. That study did not find any
significant clinical improvement above the controls; however,
the arthroscopic and histological grading scores were better in
the cell-transplanted cohort (Wakitani et al., 2002). The same
authors also reported patients treated with BM-MSC-containing
scaffolds, secured with a periosteal or synovial flap, had fibro-
cartilaginous repair tissue 12 months post-surgery (Wakitani
et al., 2007). Nejadnik and colleagues performed an observational
cohort study in which the clinical outcomes of patients treated
with ACI were compared with outcomes of patients treated
with autologous bone marrow MSCs (Nejadnik et al., 2010).
FIGURE 3 | Schematic representation of the main tissue reservoirs of
MSCs in the human body. MSCs have been found in the bone marrow,
adipose tissue, articular cartilage, synovium, skeletal muscle, dental pulp,
circulatory system, heart, brain, umbilical cord (including Wharton’s jelly), and
other connective tissues. Refer to text for further details.
Using BM-MSCs in cartilage repair was found to be at least
as effective as chondrocytes for articular cartilage repair in
improving symptoms of patients. BM-MSC repair strategies also
had the additional advantage of requiring one less knee surgery
and reducing costs. However, multiple studies have reported
that chondrogenically induced BM-MSCs hold the inherent risk
of either forming transient fibrocartilagenous repair tissue or
undergoing terminal differentiation to form calcifying cartilage,
subchondral bone overgrowth or intralesional osteophytes
(Shapiro et al., 1993; McCarthy et al., 2012). For these reasons
other types of MSCs are being actively researched.
Adipose
In the last two decades, numerous publications proved the
multipotent nature of an undifferentiated cell population, which
can be obtained from adipose tissue or liposuction samples and
which are now classified as adipose derived stem cells (ASCs)
(Zuk et al., 2001; Gimble and Guilak, 2003). These cells have been
shown to exhibit the potential for osteogenesis, chondrogenesis,
adipogenesis, myogenesis, as well as certain levels of neurogenesis
in numerous studies (Erickson et al., 2002; Adams et al., 2012;
Feng et al., 2014; Deshpande et al., 2015; Mellor et al., 2015).
Despite the fact that ASCs show similarities to bone marrow
MSCs, they exhibit a number of distinct characteristics, for
example in their cell surface markers, differentiation potential,
and abundance in the body. The great advantage of ASCs is in
their yield which when compared to 100ml of bone marrow
aspirate, up to 300-fold more stem cells can be obtained from
100 g of adipose tissue (Aust et al., 2004; Oedayrajsingh-Varma
et al., 2006).
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Another advantage of ASCs application is the relative ease
of the isolation of this cell population. Isolation of MSCs from
adipose tissue includes several very simple steps that can be
performed by anybody with routine cell culture laboratory
experience. If the sample is a native adipose tissue it has
to be minced and washed extensively to remove as much
blood as it is possible. In case of liposuction samples the
first step is unnecessary. In order to liberate cells from the
stroma of the adipose tissue, samples are incubated with
collagenase Type I followed by a gentle centrifugation (around
with 1200 g) of the digest. The floating population of mature
adipocytes can be removed and the pelleted portion of the
samples can be regarded as stromal vascular fraction (SVF).
SVF contains various cell types, such as endothelial cells,
fibroblasts, white blood cells, macrophages and the subject of our
interest, pericytes/multipotent stromal cells. These multipotent
mesenchymal cells can be selected from this mixed cell
population on the basis that they are strongly adherent to plastic
cell culture surfaces, thus the final step for the ASC isolation is
the establishment of adherent cell cultures of SVF (Estes et al.,
2010; Yu et al., 2011). These adherent cells have slim, elongated
fibroblast/mesenchymal cell-like morphology that is preserved
throughout the culturing process. If clinical application is the
aim of the ASC separation, circumstances of the isolation and
expansion procedures have to fulfill the requirements for Good
Manufacturing Practice (cGMP) guidelines, which could cause
significant delays in any clinical application of the obtained
ASCs. Nonetheless, a routine cell culture lab is fully suitable
for isolation and culturing of ASCs applied for basic research
purposes. Recently, an innovative method and device named
Lipogems R© have been developed (Bianchi et al., 2013) with
which the lipid content of lipoaspirates becomes significantly
lower and a remarkably cell-rich lipid-derivative with intact
blood vessels surrounded by high number of pericytes can be
separated. The Lipogems R© product is regarded as processed with
minimal manipulation [Regulation (EC) No. 1394/2007 of the
European Parliament and of the Council; http://eur-lex.europa.
eu/]; therefore, direct autologous application of samples obtained
in this way for clinical therapy, such as lipid replacing plastic
surgery interventions or intraarticular injection with orthopedic
indications, can be performed (Tremolada et al., 2016).
In order to be classified as MSCs isolated ASCs have
to express cell surface markers accepted for identification of
mesenchymal cells, such as CD44, CD90, and CD105, and
are expected to lack expression of the haematopoietic stem
cell markers CD45, CD34, CD133 (Dominici et al., 2006).
However, ASCs also exhibit various other cell markers which
are associated with stemness such as POU5F1, NANOG and
KLF4 (Dudakovic et al., 2014; Lv et al., 2014; Camilleri et al.,
2016). ASCs may exhibit individual variations of these marker
patterns amongst patients or depending on the locations of
the source-fat deposit (i.e., subcutaneous or visceral) in the
body (Yang et al., 2014). A common observation of numerous
investigators is that cryopreservation or long term culturing
and expansion of ASCs, similarly to BM-MSCs, reduces their
viability and differentiation potential (Gonzalez-Fernandez et al.,
2015). In summary, the above facts clearly demonstrate that ASCs
represent a multipotent cell population which is a very promising
candidate for successful tissue engineering of cartilage, bone and
other skeletal tissues.
Independent of the methods of isolation, ASCs have
demonstrated potential for chondrogenic differentiation when
expanded in appropriate monolayer conditions (Estes et al.,
2008) and then cultured with chondrogenic factors in a 3D
environment (Erickson et al., 2002). However, results are mixed
with some studies reporting ASCs have inferior chondrogenic
potential in comparison to BM-MSCs (Afizah et al., 2007), whilst
others not finding any significant difference between the two
cell types (Ronziere et al., 2010). Various growth factors have
been shown to promote in vitro cartilage formation of ASCs,
amongst them the effectiveness of TGF-β1, IGF-1 (Zhou et al.,
2016), and BMP-6 (Hennig et al., 2007) has been well established.
Besides the soluble chemical regulators of cartilage formation,
a wide range of chondrogenesis promoting scaffolds have been
developed and introduced. The scaffolds support 3D culture and
aim to mimic the extracellular environment of chondrocytes in
order to favor chondrogenic differentiation. Chitosan, collagen,
alginate, or gelatine-based scaffolds, as well as hydrogels have
been successfully applied for this purpose (Focaroli et al., 2014;
Dinescu et al., 2015; Ogawa et al., 2015). High molecular weight
HA alone or in combination with other scaffold materials
has also been proven to enhance chondrogenesis of ASCs by
several groups (Son et al., 2013; Wu et al., 2013). Recently,
ASCs transduce with an inducible interleukin 1 receptor
antagonist (IL-1Ra) transgene were seeded on the surface of
an anatomically shaped poly-caprolactone scaffold. That study
showed that advanced textile manufacture when combined
with gene delivery into ASCs can produce large and shaped
cartilaginous tissue that produces anti-inflammatory cytokines
(Moutos et al., 2016).
External physical factors, particularly optimalmechanical load
seem to play a significant positive role either during in vivo or
in vitro formation of musculoskeletal tissues, including cartilage
(for a recent review see Trumbull et al., 2016). However, only
a few studies have been published about the role of mechanical
forces in the chondrogenic differentiation of ASCs. Mechanical
load reduced the type I collagen content of bio-fabricated
cartilage generated from porcine bone marrow and infrapatellar
fat pad (IFP) derived ASCs, and in case of marrow-derivedMSCs,
calcification was also lowered by the mechanical stimuli, but the
efficacy of cartilage formation was not unambiguously enhanced
(Luo et al., 2015). In other studies, porcine, rabbit or humanASCs
seeded into various scaffolds and subjected to plated compression
or cyclic hydrostatic pressure respond to mechanical stimuli with
augmented chondrogenesis (Correia et al., 2012; Li et al., 2012;
Carroll et al., 2014). Moreover, Carrol and colleagues proposed
that responsiveness of multipotent ASCs to external physical
cues might be considered as a functional assay to evaluate their
therapeutic potential. Two recent reviews summarize efforts to
fabricate or regenerate articular cartilage with application of
ASCs (Wu et al., 2013; Bielli et al., 2016). Therefore, current
evidence demonstrates that adipose-derived MSCs can provide
a readily available cells source that have shown clinical promise
for articular cartilage repair (Perdisa et al., 2015).
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Resident MSCs within the Synovial Joint
Tissues
Articular Cartilage
Development of articular cartilage progresses through
appositional growth driven by a progenitor/stem cell
subpopulation that resides in the articular surface (Archer
et al., 2003b). Adult articular cartilage was thought to be
devoid of stem cells or progenitors but recent work by multiple
groups has demonstrated their presence in vivo and in vitro
(Alsalameh et al., 2004; Dowthwaite et al., 2004; Fickert et al.,
2004; Grogan et al., 2009;Williams et al., 2010; Pretzel et al., 2011;
Nelson et al., 2014). Tissue specific MSCs have now been isolated
from healthy and osteoarthritic adult articular cartilage. These
cells are capable of multipotent differentiation, preferentially
bind fibronectin and exhibit a high colony forming efficiency,
and they have been shown to grow for over 70 population
doublings in vitro (Williams et al., 2010). Cartilage-derived
chondroprogenitors (CPCs) are colony-forming cells enriched
by differential adhesion to fibronectin and are positive for CD90,
CD105, CD166, STRO-1, Notch-1 and negative for CD45 and
CD34 cell surface markers and able to undergo multi-lineage
differentiation. Bovine and human articular CPCs retain SOX9
expression and exhibit telomere maintenance after extensive
cell expansion of clonal isolates, and retain their multipotent
differentiation capacity (Khan et al., 2009; Williams et al., 2010).
The discovery of cartilage-derived progenitors, whilst a useful
cell source for tissue engineering applications, has inevitably
led to a greater focus on their role in intrinsic repair processes
particularly during OA disease. Chondrocyte clusters are a well-
defined feature of osteoarthritic cartilage and are hypothesized
to result as a proliferative response to injury where cells are
aberrantly constrained within a single lacuna due to unknown
reasons (Lotz et al., 2010). The presence of a highly mitotic
subpopulation of cells within osteoarthritic cartilage suggests
that progenitor cells exist within the tissue either the result of
chondrocyte dedifferentiation or re-activation.
In the absence of specific phenotypic markers for CPCs
a number of studies have used fluorescence-activated cell
sorting for various combinations of MSC cell surface antigens
including CD9, CD44, CD90, and CD166 to detect progenitor-
like subpopulations in osteoarthritic cartilage. Results show that
2–17% of cells within OA cartilage exhibit antibody reactivity to
MSC-like cell surface determinants and can undergo tri-lineage
differentiation to form fat, bone and cartilage (Alsalameh et al.,
2004; Fickert et al., 2004; Pretzel et al., 2011). Colony-forming
assays using differential adhesion to fibronectin and Hoescht
dye exclusion assay have also been used to identify CPCs in
osteoarthritic cartilage, where two studies found no difference in
their frequency between normal and diseased cartilage (Grogan
et al., 2009; Nelson et al., 2014). Koelling et al. were able to
isolate a highly proliferative population of CPCs from human
osteoarthritic cartilage solely through their enhanced migratory
ability (Koelling et al., 2009). In vitro studies have shown
hypocellular cartilage formed by blunt impact or scratching can
be repopulated by adjacent chondroprogenitor-like cells with
their defining characteristic being overexpression of markers
for cellular proliferation (Seol et al., 2012). Studies using
blunt force trauma to replicate aspects of post-traumatic OA
have similarly identified chondrocytes capable of proliferation
and Notch-1 expression as those capable of promoting an
instrinsic repair response (Henson et al., 2005). Therefore,
current evidence demonstrates that normal, injured and diseased
articular cartilage contain a viable pool of progenitor cells with
mesenchymal stem cell-like characteristics with an inherent
potential for maintenance and repair.
There are clear advantages associated with the use of
articular cartilage-derived MSCs in cell-based cartilage therapy.
Firstly, these cells are isolated from local tissue and have been
shown to possess sufficient proliferative capacity for expansion
without losing their propensity for chondrogenic differentiation.
Compared to MSCs from bone marrow and adipose-derived
progenitors, articular cartilage-derived stem cells are believed
to be further along in their commitment to the chondrogenic
lineage, primed to differentiate to form hyaline cartilage, making
them a logical choice for tissue engineering (Jayasuriya and
Chen, 2015). Moreover, articular CPCs, unlike marrow stromal
mesenchymal cells do not terminally differentiate toward an
epiphyseal lineage producing hypertrophic chondrocytes. CPCs
do not generate a collagen type X-rich matrix or express RUNX2
transcription factor protein but make predominantly collagen
type II and a hyaline cartilage-like matrix upon chondrogenic
differentiation (Williams et al., 2010; McCarthy et al., 2012). Stem
cell populations within articular cartilage offer a potentially novel
and promising cell source for tissue engineering. Identification of
reliable markers and isolation methods are essential in ensuring
the most effective repair.
Synovium and Synovial Fluid
MSCs derived from synovial membranes (SM-MSCs) can be
expanded in vitro for prolonged periods with limited cell
senescence and can be consistently induced into multilineage
differentiation pathways regardless of donor age or serial passage
(Nishimura et al., 1999; De Bari et al., 2001a). They express MSC
phenotypic markers and are negative for hematopoietic markers
as shown in Table 1. Unlike CPCs and BM-MSCs, SM-MSCs in
vitro do not exhibit telomerase activity, it is therefore postulated
that the telomere length and capacity for self-renewal is regulated
through telomerase independent mechanisms (Blasco et al.,
1999; De Bari et al., 2001a). Previous studies have shown
that SM-MSCs have greater chondrogenic potential than donor
matched BM-MSCs, ASC, and periosteum- or muscle-derived
stem cells (Sakaguchi et al., 2005; Futami et al., 2012). When
chondrogenic differentiation was induced with BMP-2, TGF-
β and dexamethasone in 3D pellet culture, synovial-derived
MSCs consistently produce larger cartilaginous pellets than bone
marrow MSCs from the same patients (Shirasawa et al., 2006).
Intra-articular injection of SM-MSCs in rat, rabbit, porcine
and primate meniscal defect and injury models have shown
that SM-MSCs can promote meniscus regeneration and provide
protection of medial femoral articular cartilage (Hatsushika et al.,
2013, 2014; Ozeki et al., 2015; Kondo et al., 2016). In early clinical
trials SM-MSCs have shown promise for treatment of articular
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cartilage defects, producing hyaline cartilage repair tissue (Sekiya
et al., 2015). In a 3-year follow-up study, defects transplanted
with SM-MSCs showed improved MRI, qualitative histology and
Lysholm scores (Sekiya et al., 2015). The advantage that synovial
MSCs hold over other cells sources is they can be grown to first
passage in only 14 days. Transplantation of synovial MSCs is also
less invasive for the patient than OATS or ACI.
MSCs have also been found in synovial fluid (SF-MSCs) of
the normal knee joint and their number increases over 10-fold
in OA or injured joints (Jones et al., 2008; Sekiya et al., 2012).
These cells have been shown to have similar phenotypes to SM-
MSCs; exhibiting significantly more clonogenicity and a lower
adipogenic capacity in vitro than matched BM-MSCs (Jones
et al., 2008). Gene profiles also demonstrate that SF-MSCs are
more similar to SM-MSCs than BM-MSCs (Morito et al., 2008).
Additionally, SF-MSCs express a similar panel of MSC surface
antigens to SM-MSCs (see Table 1). The source of SF-MSCs may
originate from shedding of joint structures such as the synovium,
IFP or articular cartilage, the frequency of which increases as
disease progresses.
Periosteum
Periosteum-derived progenitor cells (PDPCs) have been shown
to display multipotency at single cell level and meet the criteria
for classification as MSCs (De Bari et al., 2006; Choi et al.,
2008). Periosteum is a specialized connective tissue that forms a
membrane covering all bone surfaces except for articular cartilage
and sesamoid bones. It consists of a fibrous external sheet and
inner cambium layer where progenitor cells reside (Squier et al.,
1990; Ferretti et al., 2012). To isolate stem cells, periosteum
is surgically removed from bone and the cells liberated either
enzymatically or through egression from small tissue explants.
PDPCs have been identified using the classical MSC markers or
clonally isolated using limiting dilution (Lim et al., 2005; De Bari
et al., 2006; Choi et al., 2008). A very high percentage (>95%)
of cells isolated from periosteum exhibit MSC marker expression
(Lim et al., 2005; Chang and Knothe Tate, 2012). Periosteum-
derived cell preparations can form cartilage, bone and muscle
in vitro and in vivo (Gruber et al., 2001; De Bari et al., 2001b,
2006), as well as adipocytes in vitro (Sakaguchi et al., 2005; De
Bari et al., 2006).
PDPCs can remain undifferentiated through many passages
without losing their differentiation capacity (Ball et al., 2011).
Periosteum-derived cells proliferate faster than most other MSCs
in vitro (Chang and Knothe Tate, 2012; Radtke et al., 2013), linear
growth kinetics are maintained for more than 30 population
doublings that is concurrent with telomere length maintenance.
PDPC do not show signs of senescence until 80 population
doublings (De Bari et al., 2001b; Choi et al., 2008). Periosteum
cells from aging patients have been shown to retain this high
growth rate and differentiation capability unlike BM-MSCs that
show decreased longevity, telomere shortening and senescence in
aging donors (De Bari et al., 2001b, 2006; Stenderup et al., 2003;
Lim et al., 2005; Stolzing et al., 2008).
BM-MSCs and PDPCs have different osteogenic, adipogenic,
and chondrogenic potential. However, studies have reported
contradictory data indicating both that PDPC are superior and
inferior to BM-MSCs in their differentiation capacity (Yoshimura
et al., 2007; Chang and Knothe Tate, 2012). These latter studies
used different isolation protocols for PDPCs indicating the
importance of standardizedmethodologies that allow cross-study
comparison. The anatomical location of the periosteum plays
an important role in its properties and thus the harvest site
of PDPCs is important (Chang and Knothe Tate, 2012). An in
vitro study of the periosteum’s chondrogenic potential showed
that PDPCs from the ilium, scapula, and tibia are capable of
chondrogenesis, whereas periosteum from the skull exhibited
no signs of chondrogenesis (Gallay et al., 1994). The variations
seen in the differentiation capacities of PDPCs may be partly
attributable to the differences in the periosteum developmental
history.
Based on its accessibility during orthopedic surgery, and on
the ability of periosteal cells to proliferate at much higher rates
than other MSC sources, the periosteum is also an appealing cell
source for tissue engineering approaches.
Infrapatellar Fat Pad
The IFP is a tubular piece of adipose tissue located below
and behind the patella within the knee. Recent studies have
demonstrated that the IFP is a source of adipose-derived
MSCs and that these cells can be utilized for cell-based tissue
engineering and treatment for cartilage regeneration (Dragoo
et al., 2003; Wickham et al., 2003). It has been suggested that
these cells have superior chondrogenic ability compared to MSCs
derived from other tissues such as subcutaneous fat and bone
marrow (Hindle et al., 2016). IFP-derived stem cells were shown
histologically to produce more matrix than BM-MSCs and to
have increased COL2A1, ACAN, and SOX9 gene expression
(Hindle et al., 2016). Further information on adipose-derived
MSCs is provided in the adipose tissue section.
Trabecular Bone
Multiple groups have described a MSC population within
trabecular bone with the characteristics of self-renewal and
multilineage differentiation potential (Nöth et al., 2002; Sottile
et al., 2002; Tuli et al., 2003a,b; Sakaguchi et al., 2004). MSCs
were isolated from trabecular bone by digestion with collagenase
and hence referred to as collagenase-released (CR) cells. The
remaining bone fragments were then cultured andMSCs isolated
as out-growing cells once 70–80% confluence was achieved.
Stem cells isolated from trabecular bone have been shown to
be virtually identical to MSCs obtained from marrow aspirates
(Sakaguchi et al., 2004). Sakaguchi and colleagues found there
were no obvious differences in MSC yield between young and
elderly donors unlike BM-MSCs (Sakaguchi et al., 2004), though,
their proliferation rate was found to decrease with age. Although
trabecular bone-derived MSCs are capable of chondrogenic
differentiation, they have not been widely used in regenerative
strategies; this may be due to their elevated osteogenic potential
or due to the invasive and protracted isolation methodologies.
Muscle
Skeletal muscle is known to contain progenitor cells, lineage
restricted satellite cells, which are responsible for muscle
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regeneration. More recently, adult MSCs that are distinct from
satellite cells and possess the ability to differentiate into other
cell lineages have been discovered (Qu-Petersen et al., 2002;
Usas and Huard, 2007; Zheng et al., 2007). Muscle-derived stem
cells possess a high myogenic capacity and have been shown to
regenerate both skeletal and cardiac muscle (Usas and Huard,
2007). In vitro these cells have been shown to be capable of
differentiating into the osteogenic, chondrogenic, adipogenic,
myogenic and endothelial lineages, and are capable of long-term
proliferation and self-renewal (Jackson et al., 2010). Muscle-
derived stem cells can be isolated via muscle biopsy from healthy
tissue, surgical waste tissue from orthopedic reconstructions, or
surgically debrided muscle tissue following orthopedic trauma
(Qu-Petersen et al., 2002; Usas and Huard, 2007; Zheng et al.,
2007; Nesti et al., 2008).
Several cell populations with the properties of MSCs
have been identified in skeletal muscle, the best-characterized
populations are muscle-derived stem cells (MDSCs) harvested
from murine skeletal muscle. MDSCs are isolated using a pre-
plating technique, an enrichment technique that eliminates
more adherent cell types (Qu-Petersen et al., 2002), leaving
cells capable of multilineage differentiation and self-renewal.
This population has not been harvested from human muscle
tissue using differential adhesion; instead, cells with similar
in vitro characteristics have been isolated using positive
expression for endothelial cell markers CD34 and CD144, and
satellite cell marker CD56 (Zheng et al., 2007). This sub-
population of satellite cells has been termed myoendothelial cells
and are capable of osteogenic, adipogenic, and chondrogenic
differentiation. Another distinct population of multipotent cells
has been harvested from skeletal muscle following traumatic
injury (Nesti et al., 2008). Unlike MDSC, these cells are rapidly
adhering and present in high numbers during wound healing
and remodeling; it is hypothesized that multipotent cells are
recruited from their niche and proliferate to accomplish repair
(Jackson et al., 2010). The cells harvested from the injured
muscle are referred to as mesenchymal progenitor cells (MPCs)
to indicate they may not have been in a quiescent, stem cell
state when harvested (Jackson et al., 2010). MPCs have been
shown to have very similar in vitro characteristics to MDSC and
like bone marrow-derived MSCs can modulate the inflammatory
response, promote angiogenesis and inhibit apoptosis of cells
in close proximity in vitro (Djouad et al., 2010; Jackson et al.,
2010). The final stem cell population within muscle are pericytes.
Pericytes are associated with capillaries and microvessels in
almost every tissue of the body. Isolated pericytes from muscle
can differentiate into myocytes, osteoblasts, adipocytes and
chondrocytes in vitro (Jackson et al., 2010)and repair muscle in
vivo. It has been suggested that MSCs harvested from various
tissues are in fact pericytes which originated in the vasculature
of those tissues (Caplan, 2008).
Skeletal muscle is one of the most plentiful tissues in the
body and given that these cells can be obtained with minimally
invasive-biopsy procedures, there is growing evidence that
skeletal muscle may be an important clinical source of MSCs
for use in therapeutic applications (Usas and Huard, 2007).
MDSCs, pericytes and MPCs have chondrogenic potential and
might be suitable for cartilage regeneration. Muscle-derived
MSCs have been shown to express SOX9, aggrecan, and type
II collagen when differentiated into chondrocytes and when
cultured at high density form defined pellets containing cells
embedded in an ECM rich in sulphated proteoglycans and type
II collagen (Farrington-Rock et al., 2004; Matsumoto et al., 2008).
MDSCs transfected with BMP-4 have been shown to adopt a
chondrogenic phenotype in vitro and when implanted into a full
thickness osteochondral defects in rat knees resulted in persistent
repair after 24 weeks (Kuroda et al., 2006). Additionally, MDSCs
have been seeded and cultured in collagen type I scaffolds and
implanted into osteochondral defects of New Zealand white
rabbits knees (Adachi et al., 2002). That study found that after
24 weeks MDSCs gave improved regeneration of the articular
surface, collagen type II expression and construct integration,
compared with constructs seeded with chondrocytes (Adachi
et al., 2002). These experiments demonstrate the potential of
muscle-derived stem and progenitor cells for cartilage tissue
engineering.
Wharton’s Jelly
MSCs isolated from within the Wharton’s Jelly (hWJSCs)
appear to have important advantages for regenerative medicine
applications. These MSCs are relatively young given their
isolation from discarded umbilical cord collected at birth, they
can be harvested painlessly with no donor site morbidity, and
they also co-express MSC and embryonic stem cell markers and
therefore possess greater stemness properties. Wharton Jelly-
derived MSCs have short population doubling time, exhibit
non-lineage-restricted multipotency, are hypoimmunogenic and,
most importantly, they do not form tumors in immunodeficient
mice (Fong et al., 2010; Gauthaman et al., 2012). Independent
research groups have successfully differentiated hWJSCs into
chondrogenic lineage using conventional chondrogenic factors
(Hoynowski et al., 2007; Wang et al., 2011; Reppel et al.,
2015). Therefore, given the numerous advantages and the
differentiation potential of hWJSCs, these could be considered as
a potential alternative source for cartilage tissue engineering. For
a comprehensive review of Wharton’s Jelly-derived MSCs and
their clinical applications see Kim et al. (2013).
CHONDROGENESIS
Articular cartilage originally develops from multipotent
progenitor cells in the presumptive skeletal embryonic
mesenchyme. Under the influence of external and intrinsic
factors, chondroprogenitor MSCs transform into chondroblasts
and start depositing cartilage-specific ECM. Chondrogenesis
of chondroprogenitor mesenchymal cells starts with the
condensation and nodule formation and is highly dependent
on the interplay between differentiating chondrocytes and their
ECM. Understanding the mechanisms underlying the molecular
control of chondrogenesis has important implications for the
development of novel, effective treatment approaches and
improving cartilage tissue engineering.
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Intracellular Signaling Pathways
Regulating Chondrogenesis
Skeletal progenitor cells express the master chondrogenic
transcription factor SOX9, which is required for cell survival,
and maintenance of the expression of cartilage-specific markers
(e.g., collagen types II, IX, and XI, as well as CD-RAP), enzymes
involved in ECM production (e.g., chondroitin 4-sulfotransferase
CHST11), its own partners in transcription (such as SOX5 and
SOX6), as well as key signaling pathwaymediators (e.g., fibroblast
growth factor receptor-3, FGFR3) (Lefebvre and Dvir-Ginzberg,
2016). L-Sox5 and Sox6, two additional Sox transcription factor
family members which contain no transcriptional activation
domain, act in cooperation with SOX9 and are required for the
expression of Col9a1, aggrecan, and link protein (Lefebvre et al.,
2001). Given its quintessential activities in differentiating and
mature chondrocytes, it is not surprising that SOX9 is at the
heart of many of regulatory pathways during chondrogenesis,
including the hedgehog, FGF, TGF-β, BMP, Notch, and Wnt
signaling pathways (Kozhemyakina et al., 2015). The SOX9
promoter also contain binding sites for the hypoxia-inducible
factor-1α (HIF1α), nuclear factor kappa B member RELA, and
notch signaling mediator RBPj (Lefebvre and Dvir-Ginzberg,
2016). Sirtuin-1 (SIRT1), a NAD+-dependent deacetylase, is
a positive regulator for chondrogenic differentiation of MSCs
(Buhrmann et al., 2014). The Sox proteins are not the sole
transcription factors that are active in chondroprogenitor
cells; several other transcription factors such as Runt-related
transcription factor-2 (Runx2) Barx2, Nkx3.2/Bapx1, Msx1 and
2, β-catenin, Smads, Lef1, AP-1, and AP-2 are also known
to control chondrogenic differentiation (Goldring et al., 2006;
Bobick and Kulyk, 2008; Bobick et al., 2009).
As a consequence of altered gene expression patterns
following condensation, the ECM surrounding the differentiating
chondroprogenitor cells also undergoes profound changes;
cartilage-specific matrix components, most importantly
collagen type II and aggrecan are deposited as chondrogenesis
proceeds (Dessau et al., 1980). It is noteworthy that there
is a reciprocal relationship between chondrocytes and their
ECM, the characteristic composition and organization of
the matrix is essential for maintaining the appropriate
morphology, phenotype and function of differentiating and
mature chondrocytes (Cancedda et al., 2000).
Alterations in the extracellular milieu mediated by the
ECM are relayed to the intracellular signal transduction routes
by reversible pathways. Transient protein phosphorylation is
the most common posttranslational protein modification that
has an influence on the activity of many signaling proteins.
Among the intracellular factors that regulate chondrogenesis
various Ser/Thr protein kinases and Ser/Thr phosphoprotein
phosphatases were identified. All major Ser/Thr protein kinase
family members including protein kinase A (PKA) (Yoon
et al., 2000) and PKC (Matta and Mobasheri, 2014), as well
as phosphoprotein phosphatases such as PP1, PP2A, and
calcineurin (Matta et al., 2014) are essential regulators of
chondrogenesis, with either stimulatory or inhibitory effects.
Most importantly, mitogen-activated protein kinases (MAPKs)
are key components of chondrocyte signaling involved in
translating extracellular stimuli into cellular responses and
coordinate proliferation, differentiation and gene expression. The
role of MAPKs in chondrogenesis is the subject of several in-
depth review articles (Bobick and Kulyk, 2008) and is only
briefly discussed here. The three MAPK pathways contribute to
the molecular control of chondrogenesis to a different extent;
whilst JNKs seem not to be involved in this process, p38
and ERK1/2 are key regulators of chondrogenic differentiation.
The p38 pathway is primarily involved in the initiation of
condensation, whereas ERK1/2 interacts with BMP-2-induced
signaling to promote chondrogenesis (Bobick and Kulyk, 2008).
As far as the upstream mediators of the MAPK pathways are
concerned, members of the TGF-β and FGF families, retinoic
acid (RA), and integrins are reported to differentially activate
p38 and ERK1/2 MAPK pathways (Stanton et al., 2003). In BM-
MSCs, all three MAPKs were found to be positive mediators
of TGF-β1-induced chondrogenesis by inducing N-cadherin
expression (Bobick and Kulyk, 2008). The downstream targets
of MAPK signaling include lineage-specific transcription factors
including AP-1, ETS, Runx2, HIF-2α, and C/EBPβ (Lafont et al.,
2007).
Chondrogenic Differentiation of MSCs
In vitro chondrogenic differentiation of MSCs requires a
combination of a 3D environment and external growth factor
addition (Figure 4). Growth factors FGF, hedgehog, TGF-
β, BMPs, platelet-derived growth factor (PDGF), insulin-
like growth factor (IGF), epidermal growth factor (EGF),
RA and the wingless/int (Wnt) glycoproteins have been
used in various combinations to facilitate and enhance the
efficacy of in vitro chondrogenic differentiation of MSCs.
The glucocorticoid dexamethasone is used to further enhance
cartilage-specific gene expression in TGF-β1 and -3 induced
MSC cultures (Csaki et al., 2007; Bobick et al., 2009).
Members of the TGF-β superfamily are potent inducers
of chondrogenesis; TGF-β2 and TGF-β3 are more effective
mediators than TGF-β1 (Archer et al., 2003b). BMP signaling
is also necessary for chondrogenic differentiation; BMP-
2 has the strongest stimulatory effect on chondrogenesis
(Bobick et al., 2009); BMP-7 stimulates ECM synthesis and
inhibits catabolic factors (Tuan et al., 2013). IGF-1 stimulates
chondrogenic signal transduction by acting on collagen-binding
β1-integrin-receptors and IGF-1-receptors activating the Ras–
MAPK signaling pathway, and it has also been shown to stabilize
the chondrogenic phenotype by stimulating SOX9 and promote
molecular associations between ERK1/2 and SOX9 (Shakibaei
et al., 2006).
MSCs cultured in chondrogenic conditions in vitro maintain
their inherent developmental programme and undergo
hypertrophy, which results in collagen types I and X secretion,
in addition to gradual downregulation of Col2a1 in the later
stages of differentiation (Hardingham et al., 2006). In an attempt
to avoid this, strategies based on the use of molecules with
an inhibitory effect on growth plate development have being
developed. For instance, the parathyroid hormone related
peptide (PTHrP) or FGF-2 is known to downregulate Col10a1,
but also Col2a1, during in vitro chondrogenesis of adult MSCs
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FIGURE 4 | Molecular regulation of chondrogenesis. MSCs are recruited to the future sites of cartilage formation. Following migration and local proliferation cell
density increases (condensation). Cell-cell contacts trigger a set of intracellular signaling events which result in chondrogenesis accompanied by a change in cell
morphology and cartilage ECM molecule secretion. A wide range of transcription factors regulated by soluble extracellular signaling molecules acting through the
modulation of various protein kinases/phosphoprotein phosphatases play essential roles in the molecular control of chondrogenesis. See further details in text. Please
note that this list is not exhaustive.
(Kim et al., 2008). The main challenge, therefore, is to prevent
the formation of fibrous cartilage by inhibiting collagen type
I expression and secretion, but at the same time maintain or
increase collagen type II deposition during cartilage tissue
regeneration techniques. In order to avoid fibrous cartilage
formation during in vitro chondrogenesis, a more complete
understanding of the intracellular signaling events is necessary.
PERSPECTIVES AND CONCLUSIONS
Although initially considered as a tissue with a simple structure,
reproducing the stratified appearance of cartilage has proven to
be difficult. The task can be subdivided into two main phases,
regeneration of cartilage tissue, achieved through mimicking
embryonic chondrogenesis, and then remodeling of this repair
tissue to generate the adult form and hence function. In an
analogy to skin wound healing, which forms the longest part of
the repair process, remodeling of the repair cartilage is predicted
to take months or years, but, only through reconstitution of the
original form can we expect to attain long-lasting and functional
repair of osteochondral defects. We know that joint formation
and maturation are driven by progenitor cells that exhibit the
characteristics of MSCs, and therefore, these represent the best
means to enable us to direct extrinsic repair processes through
surgical intervention.
Historically, bone marrow-derived MSCs have been used to
heal cartilage defects through implantation, however there are
several important reasons why they are not optimal for durable
repair strategies. First, BM-MSCs induce fibrocartilagenous
repair, defined as matrix production that has a higher ratio of
collagen type I to II than native tissue, and secondly, there is no
evidence that this cartilage can be remodeled to form stratified
hyaline cartilage. The presence of type I collagen is per se not
deleterious, it is in fact normal for immature cartilage to be
rich in type I cartilage in the superficial zone. Type I collagen
expression is lost as the tissue matures and the protein cannot
be immunolocalized in adult articular cartilage. Collagen type I
and associated collagens types III and V reappear in injury and
disease. The inherent problem with BM-MSCs is that collagen
type I expression is an inherent part of their phenotype and
transcriptional profile, hence the formation of fibrocartilagenous
repair tissue. Themost logical use of BM-MSCs in cartilage repair
strategies would be in their native context, as a mesenchymal
stromal cell, supporting repair of the local parenchymal cells,
chondrocytes, through the supply of paracrine factors and
generation of a provisional matrix. Similarly, there is scant
evidence that other non-articular derived MSCs are capable of
generating cartilage that can be remodeled to form stratified
tissue, though each are capable of chondrogenic differentiation,
and, producing paracrine factors that enable endogenous repair,
particularly in fibrocartilagenous tissues such as menisci.
Thus far, articular cartilage-derived CPCs appear to have
the attributes to produce repair tissue conducive to long-
term repair. CPCs not only produce hyaline cartilage but also
do not undergo terminal differentiation to produce calcifying
cartilage. Most significantly, these cells are critical determinants
in the maturational transition of cartilage from one that has
an immature isotropic structure to one that is anisotropic and
mature. In general, it has been predicted that maturation is
essentially complete by puberty, which in rabbits is 3 months,
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and consequently much longer in humans. MRI imaging of
ACI treated patients predicts that the remodeling phase is
complete in 2 years, which gives a lower time estimate, although
biopsies of these repair tissues indicate that the morphology of
normal adult cartilage is seldom achieved. Work from a number
of groups has shown that osteoarthritic cartilage contains a
viable pool of CPCs that display all the qualitative attributes
of MSCs. The question arises why do CPCs persist in diseased
cartilage, and, can they be reactivated? We do not know whether
the chondrogenic activity of CPCs from diseased cartilage is
impaired in vitro compared to progenitors from normal cartilage.
Similarly we are in the dark to whether epigenetic changes
in OA CPCs resulting as a consequence of metabolic disease,
chronic overloading, or genetic deficits affect their function.
If this latter is shown to be the case, various reprogramming
strategies to alter the epigenetic profile of these cells may induce
reactivation of their chondrogenic phenotype. There is data to
suggest that CPCs reside in a stem cell niche which is demarcated
by unusual chondroitin sulfate epitopes. The loss of this niche
through proteoglycan depletion following injury and disease
may be a factor as to why CPCs become dysregulated and
unable to differentiate, though data indicates self-renewal is
not affected. Again reactivation of CPCs will have to take into
account reestablishment of the niche, either through genetic
reprogramming or presentation of the niche in biomaterials.
The presence of viable CPCs in diseased cartilage suggests
that attempts to induce repair through endogenous mechanisms
may be still within reach. MSCs from different origins may
be useful in combination therapies where CPCs produce a
hyaline repair tissue and adipose or bone marrow-derived MSCs
provide supportive paracrine factors that enhance cell viability
and reduce inflammation. When selecting the appropriate
MSC source the balance will be between expediency and
effectiveness. If we look at the options then almost every
cell type has its’ own advantages; ease of isolation, expansion,
immunomodulatory effects, and chondrogenic capacity. In
addition there are many challenges associated with isolating,
expanding and differentiatingMSCs for subsequent implantation
into degenerate joints. The physiological microenvironment of
diseased joints is hypoxic, acidic, deprived of nutrients, and
contains high concentrations of pro-inflammatory cytokines
and reactive oxygen species. Furthermore, MSCs may be
exposed to abnormal physical loads as the joint has already
been biomechanically compromised. Thus, future regenerative
medicine strategies will need to address these remaining concerns
possibly through addition of surgical interventions such joint
realignment. As next steps, focusing efforts toward achieving
standardized methods of MSC isolation, characterization, and
administration has great potential to provide powerful new
treatments. In addition, bioprinting technology offers the
possibilities of delivering cells, growth factors, and biomaterials
precisely to the required position and may be key to engineer
hyaline cartilage. Given that patients present with different
problems it is unlikely that there will be a simple “one size fits all”
answer but probably an array of solutions that need to be carefully
aligned to the individual’s requirements.
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